Home Guides Switching From Semaglutide to Tirzepatide
Switching From Semaglutide to Tirzepatide: Dose Conversion, Timing, and Cost
There is no 1:1 dose conversion between the molecules. You restart at 2.5 mg tirzepatide weekly regardless of your current semaglutide dose, take the first tirzepatide injection about seven …
There is no 1:1 dose conversion between the molecules. You restart at 2.5 mg tirzepatide weekly regardless of your current semaglutide dose, take the first tirzepatide injection about seven days after your last semaglutide dose, and re-titrate every four weeks.
On this page
Why you restart at 2.5 mg
Semaglutide and tirzepatide are different molecules with different receptor targets and different milligram scales. Being tolerant of 2.4 mg semaglutide does not make you tolerant of 10 mg tirzepatide. The GIP component in particular is new exposure for your body.
That said, switchers usually find re-titration easier than a fresh start. Around 13% report gastrointestinal symptoms on the switch versus the much higher rates seen in treatment-naive starts, because GLP-1 receptor adaptation carries over.
Timing so you don't lose ground
Semaglutide has a roughly week-long half-life. Taking your first tirzepatide dose about seven days after your last semaglutide injection keeps you on your normal weekly rhythm without stacking two active drugs. Some clinicians prefer a 10–14 day gap for people who had significant side effects; ask yours.
Expect a modest appetite rebound during weeks one to four on 2.5 mg, since that dose is weaker than a maintenance semaglutide dose. This is temporary and normal. Plan for it rather than panicking about it.
The switch is usually worth it after a plateau
Roughly one in seven people are inadequate responders to semaglutide. If you have been at a maximum tolerated semaglutide dose for three months with no further movement, SURMOUNT-5 is the evidence base for switching rather than pushing harder on the same molecule.
What it costs to switch
Compounded tirzepatide generally runs higher than compounded semaglutide — expect roughly $30–$100 more per month depending on the program. Most telehealth platforms that carry both will switch you without a full new intake, though a fresh clinical review is required.
Some programs will honour your current dose equivalent for pricing tiers even while you re-titrate clinically. Ask before you enrol; it is not standard.
Common questions
Is tirzepatide better than semaglutide?
For weight loss, yes, on the available randomized evidence. SURMOUNT-5 compared them head-to-head over 72 weeks and found 20.2% mean loss on tirzepatide versus 13.7% on semaglutide. Semaglutide retains a stronger cardiovascular outcomes label from the SELECT trial and is cheaper in compounded form.
What dose of tirzepatide do most people end up on?
Most people settle between 7.5 mg and 12.5 mg. The efficacy gain from 10 mg to 15 mg was only about 1.4 percentage points in SURMOUNT-1, while side effects and often price continue to rise. Many people never need 15 mg.
Why do tirzepatide prices go up as my dose increases?
Because some programs price by dose tier rather than charging one rate. The advertised price usually reflects the 2.5 mg starter dose, which you occupy for about four weeks. Flat-rate programs charge the same amount at every dose. Over twelve months that structural difference typically matters more than any first-month discount.
What happens if I stop taking tirzepatide?
Weight regain is expected. In SURMOUNT-4, participants who switched to placebo after 36 weeks regained 14% of body weight over the following year, while those who continued lost a further 5.5%. Obesity behaves as a chronic condition and treatment is generally open-ended.
People also ask about switching semaglutide to tirzepatide
What is switching semaglutide to tirzepatide?
Switching semaglutide to tirzepatide is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does switching semaglutide to tirzepatide apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does switching semaglutide to tirzepatide cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is switching semaglutide to tirzepatide FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.